Nucleosomal asymmetry shapes histone mark binding and promotes poising at bivalent domains
Molecular Cell · 2025
DOI: 10.1016/j.molcel.2024.12.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Cell, 2025. Verfasst von Elana Bryan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Wellcome Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3BF, UK. Hauptthemen laut MEDLINE: Histones, Nucleosomes, Mouse Embryonic Stem Cells, Histone Code. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council, European Research Council, Wellcome Trust.
Abstract (Originalsprache)
Promoters of developmental genes in embryonic stem cells (ESCs) are marked by histone H3 lysine 4 trimethylation (H3K4me3) and H3K27me3 in an asymmetric nucleosomal conformation, with each sister histone H3 carrying only one of the two marks. These bivalent domains are thought to poise genes for timely activation upon differentiation. Here, we show that asymmetric bivalent nucleosomes recruit repressive H3K27me3 binders but fail to enrich activating H3K4me3 binders, thereby promoting a poised state. Strikingly, the bivalent mark combination further promotes recruitment of specific chromatin proteins that are not recruited by each mark individually, including the lysine acetyltransferase (KAT) complex KAT6B. Knockout of KAT6B blocks neuronal differentiation, demonstrating that KAT6B is critical for proper bivalent gene expression during ESC differentiation. These findings reveal how readout of the bivalent histone marks directly promotes a poised state at developmental genes while highlighting how nucleosomal asymmetry is critical for histone mark readout and function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wellcome Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3BF, UK.
- Wellcome Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3BF, UK; Epigenetics Programme, Babraham Institute, Cambridge CB22 3AT, UK.
- Department of Molecular Mechanism of Disease, University of Zurich, 8057 Zurich, Switzerland.
- Bioinformatics Group, Babraham Institute, Cambridge CB22 3AT, UK.
- Department of Molecular Mechanism of Disease, University of Zurich, 8057 Zurich, Switzerland; Genome Biology and Epigenetics, Institute of Biodynamics and Biocomplexity, Department of Biology, Utrecht University, 3584 C…
- Wellcome Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3BF, UK; Bioanalytics, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.
Förderung
- Biotechnology and Biological Sciences Research Council
- European Research Council
- Wellcome Trust
- Swiss National Science Foundation
Zitieren
APA
Bryan, E., Valsakumar, D., Idigo, N. J., Warburton, M., Webb, K. M., McLaughlin, K. A., Spanos, C., Lenci, S., Major, V., Ambrosi, C., Andrews, S., Baubec, T., Rappsilber, J., & Voigt, P. (2025). Nucleosomal asymmetry shapes histone mark binding and promotes poising at bivalent domains. Molecular Cell. https://doi.org/10.1016/j.molcel.2024.12.002
Vancouver
Bryan E, Valsakumar D, Idigo NJ, Warburton M, Webb KM, McLaughlin KA, et al. Nucleosomal asymmetry shapes histone mark binding and promotes poising at bivalent domains. Molecular Cell. 2025. doi:10.1016/j.molcel.2024.12.002
BibTeX
@article{Bryan2025,
author = {Bryan, Elana and Valsakumar, Devisree and Idigo, Nwamaka J and Warburton, Marie and Webb, Kimberly M and McLaughlin, Katy A and Spanos, Christos and Lenci, Simone and Major, Viktoria and Ambrosi, Christina and Andrews, Simon and Baubec, Tuncay and Rappsilber, Juri and Voigt, Philipp},
title = {Nucleosomal asymmetry shapes histone mark binding and promotes poising at bivalent domains},
journal = {Molecular Cell},
year = {2025},
doi = {10.1016/j.molcel.2024.12.002}
}
EUVIMED